This review summarizes the properties, clinical use, and reversal strategies for direct oral anticoagulants compared to warfarin as of 2017.
Answers are grounded in this paper and cite their sources.
May guide NOAC selection over warfarin; leaves open need for regional outcome trials.
In this paper we describe the properties and clinical use of new anticoagulants:dabigatran (a direct thrombin inhibitor) and direct anti-Xa agents (rivaroxaban, apixaban,edoxaban ). Major studies that have been performed with these agents in comparisonwith warfarin are reported. Recommendations for use in clinical practice are provided.Information on the disappearance of the anticoagulant effect after stopping drug intakeand on the administration of agents that neutralize the effect of the new anticoagulantis provided.
No takes yet. Share an insight, caveat, or question.
Vanassche et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: